U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07064122) titled 'A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)' on July 03.
Brief Summary: The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
Study Start Date: July 04
Study Type: INTERVENTIONAL
Condition:
Haematologic Neoplasms
Intervention:
DRUG: AZD2962
AZD2962 will be administered orally once daily.
Recru...